<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37790933</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>05</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Identification of lactate regulation pattern on tumor immune infiltration, therapy response, and DNA methylation in diffuse large B-cell lymphoma.</ArticleTitle><Pagination><StartPage>1230017</StartPage><MedlinePgn>1230017</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1230017</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2023.1230017</ELocationID><Abstract><AbstractText Label="BACKGROUND">Lactate, produced through glycolytic metabolism in the tumor microenvironment (TME), is implicated in tumorigenesis and progression in diverse cancers. However, the impact of lactate on the remodeling of the TME in diffuse large B-cell lymphoma (DLBCL) and its implications for therapy options remain unclear.</AbstractText><AbstractText Label="METHOD">A lactate-related (LAR) scoring model was constructed in DLBCL patients using bioinformatic methods. CIBERSORT, XCELL, and ssGSEA algorithms were used to determine the correlation between LAR score and immune cell infiltration. Tumor Immune Dysfunction and Exclusion (TIDE), rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone (R-CHOP) cohorts, and Genomics of Drug Sensitivity in Cancer (GDSC) were utilized to predict the therapeutic response of DLBCL patients. The impact of the hub gene STAT4 on tumor biological behavior and DNA methylation was experimentally validated or accessed by the TSIDE database.</AbstractText><AbstractText Label="RESULTS">The LAR scoring model was developed based on 20 prognosis-related lactate genes, which enabled the division of DLBCL patients into high- and low-risk groups based on the median LAR score. Patients with high-risk DLBCL exhibited significantly worse survival outcomes in both the training cohorts (GSE181063) and the validation cohorts (GSE10846, GSE32918, and GSE69053), as indicated by statistically significant differences (all P&lt;0.05) and area under the curve (AUC) values exceeding 0.6. Immune analyses revealed that low-risk DLBCL patients had higher levels of immune cell infiltration and antitumor immune activation compared to high-risk DLBCL patients. Furthermore, DLBCL patients with high LAR scores were associated with a lower TIDE value and poor therapeutic efficacy of the R-CHOP regimen. GDSC analysis identified 18 drugs that exhibited significant response sensitivity in low-risk DLBCL patients. Moreover, <i>in vitro</i> experiments demonstrated that overexpression of the lactate key gene STAT4 could suppress proliferation and migration, induce cell cycle arrest, and promote cell apoptosis in DLBCL cells. Transcriptional expression and methylation of the STAT4 gene were found to be associated with immunomodulators and chemokines.</AbstractText><AbstractText Label="CONCLUSION">The lactate-based gene signature effectively predicts the prognosis and regulates TME in DLBCL. Our study underscores the role of lactate gene, STAT4, as an important tumor suppressor in DLBCL. Modulating STAT4 could be a promising strategy for DLBCL in clinical practice.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Wang, Wang, Wan, Chen, Zhang, Yang and Zhong.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jinghua</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Hematology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yanjun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Urology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wan</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Endocrinology &amp; Metabolism, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xinyuan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Digestive Medicine Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Han</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Shuo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Liye</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Hematology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>33X04XA5AT</RegistryNumber><NameOfSubstance UI="D019344">Lactic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>4F4X42SYQ6</RegistryNumber><NameOfSubstance UI="D000069283">Rituximab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019344" MajorTopicYN="Y">Lactic Acid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019175" MajorTopicYN="N">DNA Methylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069283" MajorTopicYN="N">Rituximab</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016403" MajorTopicYN="Y">Lymphoma, Large B-Cell, Diffuse</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">DNA methylation</Keyword><Keyword MajorTopicYN="N">diffuse large B-cell lymphoma (DLBCL)</Keyword><Keyword MajorTopicYN="N">lactate</Keyword><Keyword MajorTopicYN="N">prognosis</Keyword><Keyword MajorTopicYN="N">tumor microenvironment</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>6</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>4</Day><Hour>4</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37790933</ArticleId><ArticleId IdType="pmc">PMC10542897</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2023.1230017</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chapuy B, Cheng H, Watahiki A, Ducar MD, Tan Y, Chen L, et al. . Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease. Blood (2016) 127(18):2203&#x2013;13. doi:&#xa0;10.1182/blood-2015-09-672352</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2015-09-672352</ArticleId><ArticleId IdType="pmc">PMC4859195</ArticleId><ArticleId IdType="pubmed">26773040</ArticleId></ArticleIdList></Reference><Reference><Citation>Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, et al. . Outcomes in refractory diffuse large B-cell lymphoma: results from the international scholar-1 study. Blood (2017) 130(16):1800&#x2013;8. doi:&#xa0;10.1182/blood-2017-03-769620</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2017-03-769620</ArticleId><ArticleId IdType="pmc">PMC5649550</ArticleId><ArticleId IdType="pubmed">28774879</ArticleId></ArticleIdList></Reference><Reference><Citation>van Imhoff GW, McMillan A, Matasar MJ, Radford J, Ardeshna KM, Kuliczkowski K, et al. . Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the orcharrd study. J Clin Oncol (2017) 35(5):544&#x2013;51. doi:&#xa0;10.1200/JCO.2016.69.0198</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2016.69.0198</ArticleId><ArticleId IdType="pubmed">28029326</ArticleId></ArticleIdList></Reference><Reference><Citation>Younes A, Sehn LH, Johnson P, Zinzani PL, Hong X, Zhu J, et al. . Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma. J Clin Oncol (2019) 37(15):1285&#x2013;95. doi:&#xa0;10.1200/JCO.18.02403</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.18.02403</ArticleId><ArticleId IdType="pmc">PMC6553835</ArticleId><ArticleId IdType="pubmed">30901302</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies A, Cummin TE, Barrans S, Maishman T, Mamot C, Novak U, et al. . Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (Remodl-B): an open-label, randomised, phase 3 trial. Lancet Oncol (2019) 20(5):649&#x2013;62. doi:&#xa0;10.1016/S1470-2045(18)30935-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(18)30935-5</ArticleId><ArticleId IdType="pmc">PMC6494978</ArticleId><ArticleId IdType="pubmed">30948276</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyssiotis CA, Kimmelman AC. Metabolic interactions in the tumor microenvironment. Trends Cell Biol (2017) 27(11):863&#x2013;75. doi:&#xa0;10.1016/j.tcb.2017.06.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcb.2017.06.003</ArticleId><ArticleId IdType="pmc">PMC5814137</ArticleId><ArticleId IdType="pubmed">28734735</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivashkiv LB. The hypoxia-lactate axis tempers inflammation. Nat Rev Immunol (2020) 20(2):85&#x2013;6. doi:&#xa0;10.1038/s41577-019-0259-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-019-0259-8</ArticleId><ArticleId IdType="pmc">PMC7021227</ArticleId><ArticleId IdType="pubmed">31819164</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D, Tang Z, Huang H, Zhou G, Cui C, Weng Y, et al. . Metabolic regulation of gene expression by histone lactylation. Nature (2019) 574(7779):575&#x2013;80. doi:&#xa0;10.1038/s41586-019-1678-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1678-1</ArticleId><ArticleId IdType="pmc">PMC6818755</ArticleId><ArticleId IdType="pubmed">31645732</ArticleId></ArticleIdList></Reference><Reference><Citation>Salazar C, Yanez O, Elorza AA, Cortes N, Garcia-Beltran O, Tiznado W, et al. . Biosystem analysis of the hypoxia inducible domain family member 2a: implications in cancer biology. Genes (Basel) (2020) 11(2):2. doi:&#xa0;10.3390/genes11020206</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes11020206</ArticleId><ArticleId IdType="pmc">PMC7074167</ArticleId><ArticleId IdType="pubmed">32085461</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Lu S, Chen Y, Zheng L, Chen L, Ding H, et al. . Akt2 phosphorylation of hexokinase 2 at T473 promotes tumorigenesis and metastasis in colon cancer cells via nf-kappab, hif1alpha, mmp2, and mmp9 upregulation. Cell Signal (2019) 58:99&#x2013;110. doi:&#xa0;10.1016/j.cellsig.2019.03.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellsig.2019.03.011</ArticleId><ArticleId IdType="pubmed">30877036</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolinay T, Kim YS, Howrylak J, Hunninghake GM, An CH, Fredenburgh L, et al. . Inflammasome-regulated cytokines are critical mediators of acute lung injury. Am J Respir Crit Care Med (2012) 185(11):1225&#x2013;34. doi:&#xa0;10.1164/rccm.201201-0003OC</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201201-0003OC</ArticleId><ArticleId IdType="pmc">PMC3373064</ArticleId><ArticleId IdType="pubmed">22461369</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu F, Zhao Y, Pang Y, Ji M, Sun Y, Wang H, et al. . Nlrp3 inflammasome upregulates pd-L1 expression and contributes to immune suppression in lymphoma. Cancer Lett (2021) 497:178&#x2013;89. doi:&#xa0;10.1016/j.canlet.2020.10.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canlet.2020.10.024</ArticleId><ArticleId IdType="pubmed">33091534</ArticleId></ArticleIdList></Reference><Reference><Citation>He J, Chen Z, Xue Q, Sun P, Wang Y, Zhu C, et al. . Identification of molecular subtypes and a novel prognostic model of diffuse large B-cell lymphoma based on a metabolism-associated gene signature. J Transl Med (2022) 20(1):186. doi:&#xa0;10.1186/s12967-022-03393-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-022-03393-9</ArticleId><ArticleId IdType="pmc">PMC9036805</ArticleId><ArticleId IdType="pubmed">35468826</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z, Guan Q, Han X, Liu X, Li L, Qiu L, et al. . A novel prognostic signature based on immune-related genes of diffuse large B-cell lymphoma. Aging (Albany NY) (2021) 13(19):22947&#x2013;62. doi:&#xa0;10.18632/aging.203587</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.203587</ArticleId><ArticleId IdType="pmc">PMC8544299</ArticleId><ArticleId IdType="pubmed">34610582</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan J, Yuan W, Zhang J, Li L, Zhang L, Zhang X, et al. . Identification and validation of a prognostic prediction model in diffuse large B-cell lymphoma. Front Endocrinol (Lausanne) (2022) 13:846357. doi:&#xa0;10.3389/fendo.2022.846357</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2022.846357</ArticleId><ArticleId IdType="pmc">PMC9048048</ArticleId><ArticleId IdType="pubmed">35498426</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuang Z, Li X, Liu R, Chen S, Tu J. Comprehensive characterization of cachexia-inducing factors in diffuse large B-cell lymphoma reveals a molecular subtype and a prognosis-related signature. Front Cell Dev Biol (2021) 9:648856. doi:&#xa0;10.3389/fcell.2021.648856</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2021.648856</ArticleId><ArticleId IdType="pmc">PMC8166255</ArticleId><ArticleId IdType="pubmed">34079795</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X, Lu Y, Hang J, Zhang J, Zhang T, Huo Y, et al. . Lactate-modulated immunosuppression of myeloid-derived suppressor cells contributes to the radioresistance of pancreatic cancer. Cancer Immunol Res (2020) 8(11):1440&#x2013;51. doi:&#xa0;10.1158/2326-6066.CIR-20-0111</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2326-6066.CIR-20-0111</ArticleId><ArticleId IdType="pubmed">32917658</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell C, Rudensky AY. Immunotherapy breaches low-sugar dieting of tumor treg cells. Cell Metab (2021) 33(5):851&#x2013;2. doi:&#xa0;10.1016/j.cmet.2021.04.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2021.04.010</ArticleId><ArticleId IdType="pubmed">33951469</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Discovery editorial staff . Myc promotes tumorigenesis via activation of cd47 and pd-L1. Cancer Discovery (2016) 6(5):472. doi:&#xa0;10.1158/2159-8290.CD-RW2016-051</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.CD-RW2016-051</ArticleId><ArticleId IdType="pubmed">27012831</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbaum SR, Wilski NA, Aplin AE. Fueling the fire: inflammatory forms of cell death and implications for cancer immunotherapy. Cancer Discovery (2021) 11(2):266&#x2013;81. doi:&#xa0;10.1158/2159-8290.CD-20-0805</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.CD-20-0805</ArticleId><ArticleId IdType="pmc">PMC7858229</ArticleId><ArticleId IdType="pubmed">33451983</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews JM, Bhatt S, Patricelli MP, Nomanbhoy TK, Jiang X, Natkunam Y, et al. . Pathophysiological significance and therapeutic targeting of germinal center kinase in diffuse large B-cell lymphoma. Blood (2016) 128(2):239&#x2013;48. doi:&#xa0;10.1182/blood-2016-02-696856</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2016-02-696856</ArticleId><ArticleId IdType="pmc">PMC4946202</ArticleId><ArticleId IdType="pubmed">27151888</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu S, Zhou Y, Geng H, Song D, Tang J, Zhu X, et al. . Serum metabolic profile alteration reveals response to platinum-based combination chemotherapy for lung cancer: sensitive patients distinguished from insensitive ones. Sci Rep (2017) 7(1):17524. doi:&#xa0;10.1038/s41598-017-16085-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-16085-y</ArticleId><ArticleId IdType="pmc">PMC5727535</ArticleId><ArticleId IdType="pubmed">29235457</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Xu K, Guo Y, Ping L, Gao Y, Qiu Y, et al. . A high-fat diet reverses metabolic disorders and premature aging by modulating insulin and igf1 signaling in sirt6 knockout mice. Aging Cell (2020) 19(3):e13104. doi:&#xa0;10.1111/acel.13104</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acel.13104</ArticleId><ArticleId IdType="pmc">PMC7059164</ArticleId><ArticleId IdType="pubmed">31967391</ArticleId></ArticleIdList></Reference><Reference><Citation>Spisek R, Charalambous A, Mazumder A, Vesole DH, Jagannath S, Dhodapkar MV. Bortezomib enhances dendritic cell (Dc)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood (2007) 109(11):4839&#x2013;45. doi:&#xa0;10.1182/blood-2006-10-054221</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2006-10-054221</ArticleId><ArticleId IdType="pmc">PMC1885516</ArticleId><ArticleId IdType="pubmed">17299090</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson K, Ryan N, Volpedo G, Varikuti S, Satoskar AR, Oghumu S. Immune suppression mediated by stat4 deficiency promotes lymphatic metastasis in hnscc. Front Immunol (2019) 10:3095. doi:&#xa0;10.3389/fimmu.2019.03095</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.03095</ArticleId><ArticleId IdType="pmc">PMC6974475</ArticleId><ArticleId IdType="pubmed">32010142</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu X. Impact of il-12 in cancer. Curr Cancer Drug Targets (2017) 17(8):682&#x2013;97. doi:&#xa0;10.2174/1568009617666170427102729</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1568009617666170427102729</ArticleId><ArticleId IdType="pubmed">28460617</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>